Slide 1: Third Quarter 2018 Earnings Teleconference
Third Quarter 2018 Earnings Teleconference October 30, 2018
Slide 2: Introduction
Introduction Chuck Triano Senior Vice President, Investor Relations Third Quarter 2018 Earnings
Slide 3: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Our discussions during this conference call will include forward-looking statements about, among other things, our anticipated future operating and financial performance, business plans and prospects, in-line products and product candid
Slide 4: Opening Remarks
Opening Remarks Ian Read Chairman and Chief Executive Officer Third Quarter 2018 Earnings
Slide 5: CEO Perspectives
CEO Perspectives Innovative Health had another solid quarter with 5% operational growth; pleased with the performances of Ibrance, Xtandi, Eliquis, Xeljanz, Prevnar 13 and the Consumer healthcare business Essential Health saw strong growth in emerging markets and biosimilars, but overall revenue
Slide 6: Successor CEO Remarks
Successor CEO Remarks Albert Bourla Chief Operating Officer Third Quarter 2018 Earnings
Slide 7: Successor CEO Remarks
Successor CEO Remarks We are preparing for an expected era of continued growth following the impact of the loss of exclusivity of Lyrica in the U.S. Wide range of opportunities to grow our core brands Our strong, deep R&D pipeline represents a competitive advantage Making the necessary adjus
Slide 8: Financial Review
Financial Review Frank D’Amelio Executive Vice President & Chief Financial Officer Third Quarter 2018 Earnings
Slide 9: Income Statement Highlights
Income Statement Highlights ($ Millions, Except Per Share Amounts and Percentages) Third Quarter 2018 2017 Change Revenues $13,298 $13,168 1% Reported Net Income(1) 4,114 2,840 45% Reported Diluted EPS(1) 0.69 0.47 46% Adjusted Income(1) 4,661 4,059 15% Adjusted Diluted EPS(1) 0.78 0.67 16% Q3 2018
Slide 10: Impact of Foreign Exchange on Revenues and Select Adjusted Income Components
Impact of Foreign Exchange on Revenues and Select Adjusted Income(1) Components ($ Millions, Except Percentages) Favorable / (Unfavorable) Third Quarter 2018 2017 FX Impact Revenues $13,298 $13,168 ($113) (1%) Adjusted Cost of Sales(1) 2,673 2,696 212 8% COS as a Percentage of Revenues 20.1% 20.5% 1
Slide 11: 2018 Financial Guidance
2018 Financial Guidance(1) $53.0 to $53.7 billion Revenues (previously $53.0 to $55.0 billion) 20.8% to 21.3% Adjusted Cost of Sales(1) as a Percentage of Revenues (previously 20.5% to 21.5%) $14.0 to $14.5 billion Adjusted SI&A Expenses(1) (previously $14.0 to $15.0 billion) Adjusted R&D Expenses(1
Slide 12: Key Takeaways
Key Takeaways Delivered solid Q3 2018 financial results, with 2% operational Revenue growth and Adjusted diluted EPS(1) up 16% compared to the same period last year Updated and narrowed certain components of 2018 financial guidance; midpoint of Adjusted diluted EPS(1) guidance was unchanged Accompli
Slide 13: Third Quarter 2018 Earnings Teleconference Q&A Session
Third Quarter 2018 Earnings Teleconference Q&A Session October 30, 2018
Slide 14: Footnotes
Footnotes Financial Definitions Footnotes (1) Reported net income is defined as net income attributable to Pfizer Inc. in accordance with U.S. GAAP. Reported diluted earnings per share (EPS) is defined as diluted EPS attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP. (2) A